Amgen (AMGN) Receivables - Net (2009 - 2026)
Amgen (AMGN) posted Receivables - Net of $10.2 billion for Q2 2026, up 11.92% on a QoQ basis from $9.1 billion in Q1 2026, and up 17.54% year-over-year from $8.7 billion in Q2 2025.
Analysis
Amgen (AMGN) Receivables - Net (2009 - 2026) Analysis & Trends
Amgen has reported Receivables - Net for 18 years, with the latest figure at $10.2 billion in Q2 2026.
- On a quarterly basis, Receivables - Net rose 17.54% year-over-year to $10.2 billion in Q2 2026; TTM through Jun 2026 was $10.2 billion, a 17.54% increase from a year earlier, with the FY2025 full-year figure at $9.6 billion, up 41.11% from the prior year.
- Receivables - Net was $10.2 billion for Q2 2026 at Amgen, up from $9.1 billion in the prior quarter.
- The five-year high for Receivables - Net was $10.2 billion in Q2 2026, with the low at $5.1 billion in Q1 2022.
- Average Receivables - Net over 5 years is $7.1 billion, with a median of $6.9 billion recorded in 2024.
- The sharpest annual moves came in 2024 and 2025: Receivables - Net declined 6.69% in 2024, then surged 41.11% in 2025.
- Over 5 years, Receivables - Net stood at $5.6 billion in 2022, then jumped by 30.65% to $7.3 billion in 2023, then decreased by 6.69% to $6.8 billion in 2024, then soared by 41.11% to $9.6 billion in 2025, then increased by 6.87% to $10.2 billion in 2026.
- The last three Receivables - Net figures came in at $10.2 billion (Q2 2026), $9.1 billion (Q1 2026), and $9.6 billion (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn |
| 10 | BioNTech SE | 26.24 Bn | 12.58 Bn | 10.00 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 10.23 Bn |
| Mar 31, 2026 | 9.14 Bn |
| Dec 31, 2025 | 9.57 Bn |
| Sep 30, 2025 | 8.49 Bn |
| Jun 30, 2025 | 8.70 Bn |
| Mar 31, 2025 | 8.13 Bn |
| Dec 31, 2024 | 6.78 Bn |
| Sep 30, 2024 | 7.32 Bn |
| Jun 30, 2024 | 6.93 Bn |
| Mar 31, 2024 | 6.78 Bn |
| Dec 31, 2023 | 7.27 Bn |
| Sep 30, 2023 | 6.15 Bn |
| Jun 30, 2023 | 5.83 Bn |
| Mar 31, 2023 | 5.74 Bn |
| Dec 31, 2022 | 5.56 Bn |
| Sep 30, 2022 | 5.33 Bn |
| Jun 30, 2022 | 5.33 Bn |
| Mar 31, 2022 | 5.08 Bn |
| Dec 31, 2021 | 4.90 Bn |
| Sep 30, 2021 | 4.77 Bn |